Obatoclax mesylate, also known as GX15-070, is an experimental drug for the treatment of various types of cancer.

[1] Several Phase II clinical trials were completed that investigated use of obatoclax in the treatment of leukemia, lymphoma, myelofibrosis, and mastocytosis.

[5] This inhibition induces apoptosis in cancer cells, preventing tumor growth.

[6] Clinical trial results have been published for treatment of acute myeloid leukemia,[7] small cell lung cancer,[8] Hodgkin's lymphoma,[9] and myelodysplastic syndromes.

[10] Teva halted a phase III trial in patients with lung cancer before it had begun, citing "business decisions" as the reason.